Recent studies have demonstrated tremendous diversity in the genetic makeup of metastatic castration-resistant prostate cancer (mCRPC). The SU2C−Prostate Cancer Foundation (PCF) Prostate Dream Team is sequencing patient DNA and systematically comparing it with patient response to therapies. The aim is to identify biomarkers and predictors that will help physicians determine the best treatments for patients based on their molecular profiles.
- Who We Are
Stand Up To Cancer works relentlessly to offer the newest, most effective, and most promising cancer treatments to patients quickly by bringing together the best minds to collaborate, innovate, and share cancer research.
Visit Who We Are - What We Do
Stand Up To Cancer enables scientific breakthroughs by funding collaborative, multidisciplinary, multi-institutional scientific cancer research teams and investigators. Thanks to the support of our dedicated partners and the entertainment community, SU2C is able to bring widespread attention to cancer research and treatments.
Visit What We Do - Take Action
We’re all in this together! Learn how to get involved and make a monumental impact. Join our community of passionate supporters who are committed to helping patients gain rapid access to better treatments.
Visit Take Action - Clinical Trials
Research is changing the way cancer is being treated. If you’ve been diagnosed with cancer, a clinical trial may offer access to the latest and most promising science, while helping to light the path for future survivors.
Visit Clinical Trials - Research
Stand Up To Cancer was created to accelerate groundbreaking cancer research that will get promising new cancer treatments to patients quickly. We won’t stop until every cancer patient is a long-term cancer survivor.
Visit Research - For Patients & Caregivers
We understand the challenges a diagnosis can bring. Browse through our list of patient and caregiver resources to help you throughout your cancer journey, and learn more about clinical trials.
Visit For Patients & Caregivers
